论文部分内容阅读
目的探讨化疗联合免疫治疗急性白血病对患者生活质量的影响。方法选取2012年11月-2015年11月在该院血液内科收治的急性白血病患者98例,根据随机加患者知情同意的原则将98例患者分为试验组50例和对照组48例。2组均实施化疗,试验组在此基础上加自体DC-CIK过继免疫治疗。随访及评估2组的疗效及生活质量。结果试验组患者的完全缓解率为60.0%高于对照组的41.7%,差异有统计学意义(P<0.05)。治疗前2组患者的生活质量评分比较差异无统计学意义(P>0.05),治疗后2组患者的生活质量评分均高于治疗前,且试验组高于对照组,差异均有统计学意义(P<0.05)。结论急性白血病患者在传统化疗的基础上配合免疫治疗,提高了患者的完全缓解率和生活质量,值得临床推广。
Objective To investigate the effect of chemotherapy combined with immunotherapy on the quality of life of patients with acute leukemia. Methods A total of 98 patients with acute leukemia were enrolled in the Department of Hematology from November 2012 to November 2015. According to the principle of informed consent of randomized patients, 98 patients were divided into experimental group (50 cases) and control group (48 cases). Both groups were treated with chemotherapy, the experimental group on the basis of autologous DC-CIK adoptive immunotherapy. Follow-up and assessment of the efficacy and quality of life of the two groups. Results The complete remission rate was 60.0% in the experimental group and 41.7% in the control group, with significant difference (P <0.05). There was no significant difference in quality of life between the two groups before treatment (P> 0.05). After treatment, the quality of life scores of two groups were higher than before treatment, and the experimental group was higher than the control group, the difference was statistically significant (P <0.05). Conclusions Patients with acute leukemia, combined with immunotherapy based on traditional chemotherapy, improve the patients’ complete remission rate and quality of life, which is worthy of clinical promotion.